Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I/II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs G1T 38 (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors G1 Therapeutics
- 29 Mar 2018 Status changed from not yet recruiting to recruiting.
- 28 Feb 2018 Status changed from planning to not yet recruiting.
- 30 Nov 2017 New trial record